In the continuing evolution of personalized medicine, a new Yale study has found evidence to support the value of a tool that ...

In the continuing evolution of personalized medicine, a new Yale study has found evidence to support the value of a tool that measures the presence of ...

Datar Cancer Genetics (DCG) has launched the Target-MRD blood test, designed for the identification and monitoring of molecular residual disease (MRD) in individuals with solid organ cancers.

Early measurable residual disease clearance is linked to better outcomes in acute myeloid leukemia, study suggests.

In molecular genomics and oncology, Quest Diagnostics progressed with the Haystack MRD blood test for early detection of minimal residual disease (MRD) from solid tumor cancers. Zacks Investment ...

The segment's large share is attributed to the growing incidence of blood cancers, the advent of new diagnostic technologies, the rising focus on precision oncology, high investments in MRD ...

Enhanced assay granted approval by New York State’s Clinical Lab Evaluation Program (CLEP) for patients with DLBCL clonoSEQ is the only DLBCL MRD ...

The Target-MRD blood test uses a combination of tumor-informed and tumor-agnostic molecular features for personalized, accurate and more effective monitoring of molecular residual disease.

We think the MRD market has a long runway for growth but ... and it measures over 80 cancer-related genes in the patient’s blood sample. As a liquid biopsy, it can be used in cases where tumor ...